Drug Trial News

RSS

Clinical and Translational Science Institute-Children's National awards pilot grant to GW researchers

GW researchers in the School of Medicine, Jeffrey M. Bethony, Ph.D., Associate Professor of Microbiology, Immunology, and Tropical Medicine and David Diemert, M.D., FRCP(C), Associate Research Professor of Microbiology, Immunology, and Tropical Medicine and Director of Clinical Trials for the Sabin Vaccine Institute's Product Development Partnership (PDP), have been awarded a Pilot Grant from the Clinical and Translational Science Institute-Children's National.

25 Apr 2012

Positive results from Repligen's RG3039 Phase 1 study for spinal muscular atrophy

Repligen Corporation today announced positive results from a Phase 1 study to evaluate the pharmacokinetic (PK) and safety profile of RG3039, a novel small molecule drug candidate for the potential treatment of spinal muscular atrophy (SMA).

25 Apr 2012

Omega-3 supplements do not improve diastolic function in older adults

Over the past three decades, researchers have firmly established that the omega-3 fatty acids in fish oil, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have healthy effects on the heart. Omega-3 fatty acids seem to help both in preventing cardiovascular disease as well as in preventing future heart attacks, strokes, and other adverse events in people who have established cardiovascular disease.

25 Apr 2012

S-equol effective in reducing menopausal hot flashes, muscle and joint pain among U.S. women

A dose of 10 milligrams (mg) daily of S-equol delivered via a newly developed fermented soy germ-based nutritional supplement is as effective as a standard dose of soy isoflavones at reducing hot flash frequency significantly and is even more effective for relieving muscle and joint pain, according to a peer-reviewed study in US postmenopausal women published in the June Journal of Women's Health, available now as a Fast Track article online ahead of print.

25 Apr 2012

Clinical trial to evaluate IGF-1 in children with SHANK3 deficiency

In an important test of one of the first drugs to target core symptoms of autism, researchers at Mount Sinai School of Medicine are undertaking a pilot clinical trial to evaluate insulin-like growth factor (IGF-1) in children who have SHANK3 deficiency (also known as 22q13 Deletion Syndrome or Phelan-McDermid Syndrome), a known cause of autism spectrum disorder (ASD).

25 Apr 2012

Biogen Idec announces positive data from oral BG-12 second Phase 3 trial on RRMS

Today Biogen Idec announced that detailed positive data from CONFIRM, the second Phase 3 clinical trial of oral BG-12 (dimethyl fumarate) in people with relapsing-remitting multiple sclerosis (RRMS), will be presented in three platform presentations at the 64th Annual Meeting of the American Academy of Neurology (AAN) in New Orleans.

25 Apr 2012

Protein blend intake following resistance exercise may build muscles

Today at Experimental Biology 2012, Dr. Blake Rasmussen and colleagues presented a new and first-of-its-kind clinical study: "Effect of Protein Blend vs. Whey Protein Ingestion on Muscle Protein Synthesis Following Resistance Exercise." The results of this study suggest that a protein blend (combination of soy, whey and casein) may be best to consume post-workout for building muscle. Specifically, the blend of proteins in this study showed an increase in a person's "anabolic window."

24 Apr 2012

Gabapentin drug helps people to quit cannabis

Scientists at The Scripps Research Institute have found clinical evidence that the drug gabapentin, currently on the market to treat neuropathic pain and epilepsy, helps people to quit smoking marijuana.

24 Apr 2012

R-Tech Ueno completes RK-023 phase I study on hypotrichosis of the eyelashes

R-Tech Ueno is pleased to announce the completion of a phase I clinical study of RK-023, a new compound that is being developed for the treatment of hypotrichosis of the eyelashes.

24 Apr 2012

Medgenics seeks FDA Orphan Drug Designation for INFRADURE to treat hepatitis D

Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that it has filed for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for INFRADURE for the treatment of hepatitis D.

23 Apr 2012

RVX-208 molecule increases apolipoprotein A-I production

Resverlogix Corp. today announces the "Mechanism of Action" (MoA) by which RVX-208 increases apolipoprotein A-I (ApoA-I) production.

23 Apr 2012

Oligomerix to advance tau protease inhibitor program with $2M Series A financing

Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease and related neurodegenerative disorders, announced today the completion of approximately $2 million in Series A financing, which includes both issuance of new convertible preferred shares and debt conversion.

23 Apr 2012

JT/Torii report positive results from ferric citrate Phase 3 study for hyperphosphatemia

Keryx Biopharmaceuticals, Inc., announced today that its Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd., has announced positive top-line results from a Phase 3 study of ferric citrate in Japan for the treatment of hyperphosphatemia in end-stage renal disease patients on hemodialysis.

23 Apr 2012

Asubio commences SUN13837 Phase 2 clinical trial for acute spinal cord injury

Today, Asubio announced the initiation of a landmark Phase 2 clinical trial of SUN13837, an investigational medication being developed to improve neurological function in patients with newly diagnosed acute spinal cord injury.

23 Apr 2012

Neutra announces clinical trials for Pure Plus Weight Loss supplement

Neutra Corp., an emerging nutraceuticals provider, is pleased to announce that clinical trials are now underway on its new and improved weight-loss supplement, Pure Plus Weight Loss.

23 Apr 2012

MicuRx completes MRX-I Phase 1 trial on MRSA and VRE infection

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced the completion of its Phase 1 clinical trial for MRX-I, its first development-stage antibiotic drug candidate.

23 Apr 2012

VeriStrat test may be useful for NSCLC clinical decision-making

Results from the combined analysis of two European Phase II trials were presented today at the 3rd European Lung Cancer Conference in Geneva, Switzerland. The VeriStrat retrospective analysis was performed on serum samples from advanced non-squamous non-small cell lung cancer (NSCLC) patients treated with the combination therapy bevacizumab plus erlotinib.

21 Apr 2012

LCIG improves quality of life, reduces symptoms of Parkinson's

A recent clinical trial conducted at Evergreen Healthcare shows that a new form of a common drug used to treat Parkinson's Disease greatly improves the quality of life for patients and reduces the affects of symptoms such as tremors, slowness, stiffness and difficulty walking.

21 Apr 2012

Results from Boehringer Ingelheim's afatinib Phase III lung cancer trial

Highly anticipated results from LUX-Lung 3, the pivotal Phase III lung cancer trial investigating Boehringer Ingelheim's front running oncology investigational compound, the ErbB Family Blocker afatinib, in patients with EGFR mutations, will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from 1 - 5 June 2012.

21 Apr 2012

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive results from its Phase I clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.

21 Apr 2012